Page results
-
The Royal National Ear Nose and Throat Hospital is a national and international centre for voice disorders. The voice service includes four consultant laryngologists, eight speech and language therapists and specialist nurses.
-
This page explains what you can expect during recovery from your CAR T-cell therapy.
-
Professor Lunn's specialist clinical and research interests are in the inflammatory neuropathies, particularly Guillain-Barré syndrome, CIDP and paraproteinaemic neuropathies.
-
This page provides information for employers, teachers, special needs education coordinators (SENCo) and other professionals who work alongside someone with Galactosaemia.
-
Dr Phillpotts is a consultant gastroenterologist at University College Hospital with a special interest in ERCP, EUS and pancreatobiliary medicine.
-
Professor Hough is a consultant heamatologist at UCLH. She has specialist expertise in the management of acute lymphoblastic leukaemia in teenagers and young adults, and the use of umbilical cord blood as an alternative source of haemopoietic stem cells.
-
The aim of this page is to give information about how we induce labours.
-
Support patients in hospital this Christmas and the staff looking after them by donating to our UCLH Charity Gift of Giving Appeal.
-
Cerebral palsy (CP) is a permanent disorder affecting movement in different parts of the body often accompanied by disturbances of sensation, cognition, communication, perception, behaviour and musculoskeletal problems.
-
Information about incentive spirometry (IS) for adults with sickle cell disorder.
File results
-
FOI/2024/0393 - Translation service/ communication spend
-
FOI/2024/0385 - Immunoglobulin vials (by brands) distributed to patients
-
FOI/2024/0381 - Proton Beam Therapy Centre material use, architectural technology and performance
-
FOI/2024/0380 - Appraisal review/ Responsible Officer/ Revalidation Officer
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust